Nereus Pharmaceuticals engages in the discovery and development of therapeutics for the treatment of infectious diseases and inflammation.
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 25, 2010 | Series E | $20M | 1 | — | — | Detail |
Aug 9, 2007 | Series D | $45M | 4 | BankInvest Biomedical Venture | — | Detail |
Oct 19, 2005 | Series D | $42.60M | 3 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
BankInvest Biomedical Venture | Yes | Series D |
Advent International | — | Series E |
Eminent Venture Capital | — | Series D |
Boston Life Science Venture | — | Series D |
Sanofi | — | Series D |
Lotus BioScience Ventures | — | Series D |